🏆 Deal of the Week · KW 5/2024
Enterprise Therapeutics raised GBP 26 million in a Series B follow-on financing round, announced in January 2024; no valuation was disclosed. The round was backed by a syndicate of six investors including Versant Ventures, Panakes Partners, and Novartis Venture Fund, with no single lead investor publicly designated.
Enterprise Therapeutics — key deal facts
| Company | Enterprise Therapeutics |
| Founded | 2014 |
| Headquarters | Brighton, United Kingdom |
| Amount raised | GBP 26M |
| Valuation | Valuation Remains Undisclosed |
| Round | Series B |
| Investors | Versant Ventures Panakes Partners Novartis Venture Fund IP Group Forbion Capital Partners Epidarex Capital |
| Sectors | HealthTech |
Who invested in Enterprise Therapeutics?
The Series B attracted Versant Ventures, Panakes Partners, Novartis Venture Fund, IP Group, Forbion Capital Partners, and Epidarex Capital. The investor mix is notable for combining transatlantic life-science specialists with a strategic corporate venture arm in Novartis Venture Fund, signalling both financial and potential strategic interest in Enterprise Therapeutics' pipeline. IP Group's continued participation also underscores the company's origins in UK academic research commercialisation.
What does Enterprise Therapeutics do?
Enterprise Therapeutics is a UK-based biopharmaceutical company founded in 2014 and headquartered in Brighton, East Sussex. The company develops inhaled, disease-modifying therapies targeting mucus congestion in respiratory diseases including cystic fibrosis, asthma, and chronic obstructive pulmonary disease (COPD). Its lead asset, ETD001, is an inhaled epithelial sodium channel (ENaC) blocker designed to enhance mucus clearance and improve lung function, currently advancing through Phase 2 clinical trials. The company was co-founded and is led by CEO John Ford, who brings more than 20 years of biotechnology experience to the role.
Enterprise Therapeutics valuation & multiples
Explore the benchmarks: Series B HealthTech.
Frequently asked questions
How much did Enterprise Therapeutics raise in its Series B?
Enterprise Therapeutics raised GBP 26 million in a Series B follow-on financing round announced in January 2024.
What is Enterprise Therapeutics's valuation?
Enterprise Therapeutics's valuation was not disclosed in connection with this Series B round.
Who invested in Enterprise Therapeutics?
The Series B round was backed by Versant Ventures, Panakes Partners, Novartis Venture Fund, IP Group, Forbion Capital Partners, and Epidarex Capital.
When was Enterprise Therapeutics founded and where is it based?
Enterprise Therapeutics was founded in 2014 and is headquartered in Brighton, United Kingdom.
Source: original announcement — read the full report.